If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. In light of the recent options history for Biogen, it's now ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

depression and ALS, are a key part of Biogen's strategy to combat the increased competition in the MS space. That includes the coming launch of a tysabri biosimilar in the U.S. and generic ...

HI-Bio unveiled positive Phase 2 data of its kidney disease drug ... In 2023, Biogen had four product approvals in Alzheimer’s, Friedreich’s ataxia, postpartum depression and ALS.

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. In light of the recent options history for Biogen, it's now ...